LO3A.F LONZA GROUP UNSP.ADR 1/10

Healthcare Biotechnology Frankfurt Exchange
71.00 EUR
Close of Nov 12, 2026
49.07 73.00
Market cap
EUR 49.6B
P/E
43.6x
P/B
5.67x
ROE
-3.0%
Dividend yield
0.76%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is LO3A.F undervalued?

Graham number

The Graham number of LONZA GROUP UNSP.ADR 1/10 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LONZA GROUP UNSP.ADR 1/10 fundamental analysis

No fundamental analysis for LONZA GROUP UNSP.ADR 1/10 yet.

LONZA GROUP UNSP.ADR 1/10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LONZA GROUP UNSP.ADR 1/10

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manuf…

Full company profile